0.30
0.30 (-16.99%)
As of Nov 03, 2023
Frequency Therapeutics, Inc. [FREQ]
Source:
Company Overview
Korro Bio, Inc. is a clinical-stage biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases.
| Country | United States |
| Headquarters | lexington, massachusetts |
| Phone Number | 781-315-4600 |
| Industry | manufacturing |
| CEO | David L. Lucchino |
| Website | www.korrobio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $2.3 |
| Operating Profit | $-91.9 |
| Net Income | $-83.6 |
| Net Cash | $-114.1 |
Profit Ratios
| Gross Margin | $2.3 |
| Operating Margin | -4,047.1 |
| Profit as % of Revenues | -2.7% |
| Profit as % of Assets | -37.3% |
| Profit as % of Stockholder Equity | -52.1% |
Management Effectiveness
| Return on Equity | -52.1% |
| Return on Assets | -36.9% |
| Turnover Ratio | 1% |
| EBITA | $-91.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $226.2 |
| Total Liabilities | $65.8 |
| Operating Cash Flow | $-60.1 |
| Investing Cash Flow | $-123.3 |
| Financing Cash Flow | $69.4 |
